Tag: Arbutus Biopharma


Arbutus Biopharma Corp (NASDAQ: ABUS) And Antios Therapeutics Enter Into A Partnership To Treat The Hepatitis B Virus (HBV) Infection

Arbutus Biopharma Corp (NASDAQ: ABUS) has announced that it has recently joined hands with Antios Therapeutics. The two companies have entered into a clinical collaboration is to evaluate a triple combination of Arbutus’ proprietary GalNAc delivered RNAi therapeutic, AB-729, Antios’ proprietary active site polymerase inhibitor nucleotide (ASPIN), ATI-2173, and Viread […]